Refractory Acute Myeloid Leukemia (AML)
Also known as: Acute Myeloid Leukaemia Refractory / Acute Myeloid Leukemia, Refractory / Acute, refractory Myeloid Leukemia / Acute Myeloid Leukemia Refractory / Refractory AML / Refractory Acute Myeloid Leukemia / Refractory Acute Myelogenous Leukemia (AML) / Refractory Acute Myelogenous Leukemia / Acute, refractory Myelogenous Leukemia / Refractory acute myeloid leukemia (disorder)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB00631 | Clofarabine | A purine nucleoside used to treat relapsed or refractory acute lymphoblastic leukemia in patients 1 to 21 years old. |
| DB13874 | Enasidenib | An isocitrate dehydrogenase-2 inhibitor used to treat relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation. |
| DB00056 | Gemtuzumab ozogamicin | A monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia. |
| DB14568 | Ivosidenib | An isocitrate dehydrogenase-1 inhibitor used to treat acute myeloid leukemia and cholangiocarcinoma in adults with a susceptible IDH1 mutation. |
| DB16267 | Olutasidenib | An isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation as detected by an FDA-approved test. |